All News

The Enhancing Oncology Model, announced in July 2022 during the final days of its predecessor, the Oncology Care Model (OCM), has a similar framework as the early alternative payment model for oncology in Medicare, but there are key differences in reimbursement and especially in practices’ requirements to take on risk.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses best practices that physicians and parents of infants with atopic dermatitis (AD) can do to help manage flare- ups, as well as barriers to care, which he presented at the Revolutionizing Atopic Dermatitis conference.

The annual award recognizes rising leaders in the field of managed care research who are already making exceptional long-term contributions

Dayna Johnson, PhD, MPH, MSW, MS, the Rollins School of Public Health at Emory University, discusses principal findings from the analysis of a 35-day sleep intervention study that utilized a mobile mindfulness app to manage stress and anxiety combined with healthy sleep practices.

Red blood cell distribution width (RDW) may be a good biomarker for chronic obstructive pulmonary disease (COPD) severity, study finds.

Merck sues to stop Medicare drug price negotiations; doctors delay lifesaving therapies due to cancer drug shortages; a federal appeals court will hear Affordable Care Act coverage prevention case.

Posters presented at SLEEP 2023 estimated the prevalence of idiopathic hypersomnia as well as incidence of comorbidities.

Among women on Medicaid, the prevalence of Kaposi sarcoma—a cancer commonly associated with HIV—was 82 times higher in women with HIV compared with women without HIV.

In patients with ejection fraction greater than 40% who were stabilized after a worsening heart failure event, use of combination sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels compared with valsartan alone.

Travis Brewer, vice president of payer relations at Texas Oncology, discusses the importance of oncologists’ collaboration with payers to improve value-based care.

It’s important to consider the social context, the social ecology, and the family environment when investigating behavioral sleep problems among children and adults, noted Arielle Williamson, PhD, DBSM, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine.

While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

Judite Blanc, PhD, is lead author on the abstract, “Social Determinants of Sleep Disorders Among Multiethnic Americans in the NIH All of Us Research Program,” which was presented today at SLEEP 2023.

When multiple trastuzumab biosimilars entered the US market in quick succession, they were able to do something other biosimilars have not in the United States: drive down the cost of the originator biologic.

The sharp reduction in costs for hospitalization from respiratory syncytial virus (RSV) in infants 3 months and younger after the COVID-19 pandemic outweighed the cost increase for children aged 3 to 24 months.

Mark Fendrick, MD, speaks about how how minority populations may be the most at risk following the Braidwood ruling on preventive care.

A retrospective analysis of data of patients with chronic obstructive pulmonary disease (COPD) suggests that mucus plugs could contribute to patient mortality, offering a possible treatment target.

Health restrictions on transgender adults and children; weight-loss companies to include obesity drugs; hormone patches or creams for menopause may have lower blood pressure risk than pills

Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.

In this interview, Tycel Phillips, MD, associate professor of medicine, Division of Lymphoma and Bone Marrow Transplantation, City of Hope, Duarte, California, discusses the advancements that are shaping the future of B-cell lymphoma treatment, as well as access barriers.

In March 2023, national telehealth utilization rose 1.8%, up from 5.5% of medical claim lines in February, according to new data from FAIR Health’s Monthly Telehealth Regional Tracker.

In early findings, the antibody drug conjugate created strong responses in multiple tumor types where patients have unmet need.

Bhagirathbhai R. Dholaria, MD, assistant professor of medicine in the Department of Hematology-Oncology at Vanderbilt University Medical Center, discussed findings from the phase 2 TRiMM-2 trial of talquetamab plus daratumumab in multiple myeloma.

Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.

Although older patients generally accept electronic visits (e-visits) conducted via asynchronous messages, nearly two-thirds said they prefer visit types with synchronous dialogue.

Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.

With Medicare-aged Americans accounting for over 15% of the population and significant health care costs, stakeholders have leveraged various approaches, including the Medicare Current Beneficiary Survey, for estimating costs.

The decreasing cost of DNA sequencing has contributed to an uptick in genomic sequencing for precision diagnostics in rare diseases.

The new classifications included several major changes and may help identify different subtypes.